Biological Signal Processing Ltd. (Tel Aviv, Israel) received FDA clearance for its high-resolution ECG technology to be used to diagnose heart attacks, according to the Globes newspaper. HyperQ, as it’s called, the technology gives a much closer look at the QRS complex of an ECG, which holds clues about the patient’s cardiac condition.
Previously, the technology was intended for use during a traditional stress test, aiding in more accurately assessing the patient’s cardiopulmonary health. The new approval is intended for at-rest use of the technology for diagnosing myocardial infarctions.
Some details about the HyperQ system according to the product page:
- The HyperQ™ System is a dual mode, top of the line device combining all the functionalities of standard stress ECG systems with the unique HyperQ analysis. Importantly, the test performed using the HyperQ system utilizes standard ECG stress protocols providing the physician with a familiar procedure of standard duration. The only difference is that the HyperQ system provides enhanced ECG analysis in addition to all standard ECG parameters.
- HyperQ™ refers to acquisition of the ECG signal at high frequencies. Traditional ECG is read at low frequencies. BSP harnesses the valuable information found in the higher frequencies to extract more accurate results from the ECG tracing.
- HyperQ™ prevents unnecessary exposure to radioactive or invasive procedures in patients that are inherent in other advanced IHD diagnosis systems. By using the HyperQ System you can attain levels of sensitivity and specificity similar to those of radioactive procedures.
- Accuracy equivalent in men and women. While Stress test accuracy in women is notoriously low, the HyperQ diagnosis performs equally well in men and women, thus allowing for a dramatically enhanced diagnosis in women.
- Using the HyperQ™ System significantly reduces health care system costs. Accurate diagnosis by the HyperQ™ saves the time and cost of other further, expensive IHD tests.
- Clinical trial results have been presented at conferences in Europe and the US and published in leading cardiology journals. To date, thousands of patients have been examined by the HyperQ™ System in controlled clinical studies, hospitals and private physician offices.
Via Globes: BSP receives FDA approval for ECG test…